Deal Structure & Financial Terms

The agreement is structured as a heavily backloaded partnership. Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments, with the vast majority of the $2.5 billion total value contingent on successful development, regulatory, and commercial outcomes .

• Upfront and near-term milestones: Up to $18 million .
• Total potential value: Over $2.5 billion including development, regulatory, and commercial milestone payments .
• Royalties: Insilico will receive single-digit royalties on net sales upon commercialization .
• Revenue-sharing: Additional revenue-sharing income is included in the potential value .
• Scale context: This is Insilico's second deal exceeding $2 billion in under three months .

Therapeutic Focus: CNS Neuroimmune Disorders

The collaboration targets central nervous system (CNS) neuroimmune disorders, a therapeutic area with high unmet medical need. The specific disease categories include:

• Neuroinflammatory conditions
• Neurodegenerative conditions (e.g., disorders involving progressive neuronal loss)
• Rare neurological diseases

The companies plan to identify multiple new biological targets and derive drug candidates against them, marking a focused bet on the intersection of immunology and neuroscience — a space historically difficult for traditional drug discovery due to the blood-brain barrier and complex disease biology .

How the Deal Works Operationally

• Insilico's role: Applies its Pharma.AI generative AI platform — including target discovery, molecule generation, and prediction engines — to identify and optimize novel drug candidates for neuroimmune targets .
• SK Biopharmaceuticals' role: Provides development and commercialization infrastructure, including clinical development expertise, regulatory capabilities, and commercial reach, particularly in Asian and global markets .
• Joint work: The agreement is described as a joint research agreement and a wide-ranging R&D partnership, not merely a licensing deal .

Strategic Context for Each Company

For Insilico Medicine:
This is the second mega-deal for Insilico in 2026. In March 2026, it signed a $2.75 billion collaboration with Eli Lilly ($115 million upfront plus up to $2.63 billion in milestones) covering broader therapeutic areas . The SK deal validates Insilico's platform for CNS neuroimmune applications specifically. The deal diversifies Insilico's partnership base beyond big pharma into Asian biotech leaders, and it follows its IPO on the Hong Kong Stock Exchange (ticker 3696.HK) . Insilico's shares rallied on the news .

For SK Biopharmaceuticals:
SK Biopharmaceuticals is a South Korean biotech known for developing and commercializing CNS drugs globally, including its marketed epilepsy drug Xcopri (cenobamate) . This deal is SK's first AI-driven drug discovery partnership and represents its strategic pivot toward integrating AI into its R&D pipeline . It was the first partnership disclosed by a Korean corporation at BIO 2026 . The deal also aligns with a broader SK Group–Nvidia AI alliance that is expanding beyond semiconductors into pharma and biotech. SK Group chairman Lee Dong-hoon has signaled this push, with Nvidia and SK Biopharm exploring joint AI infrastructure work .

Broader Momentum in AI-Driven Drug Discovery

The Insilico–SK Biopharm deal fits into a clear pattern of accelerating, large-scale AI pharma partnerships in 2026:

• Lilly–Nvidia ($1B): In January 2026, Eli Lilly and Nvidia announced a $1 billion co-investment over five years to build an AI innovation lab for drug discovery .
• Lilly–Insilico ($2.75B): In March 2026, Lilly committed up to $2.75 billion to partner with Insilico on AI-discovered drugs .
• AI as infrastructure: Nvidia's BioNeMo platform is being positioned as foundational AI infrastructure for pharma, with multiple partners building on it .
• Capital flowing: In Q1 2026 alone, AI drug discovery companies raised substantial capital, including a $787 million round for Earendil Labs .
• BIO 2026 theme: The convention's opening news was this deal, underscoring that AI-driven discovery is now a central theme at the industry's largest annual gathering .

The key signal: Big pharma and Asian biotech leaders are no longer experimenting with AI — they are committing billions in backloaded milestone structures that tie payments directly to AI-discovered candidates reaching the clinic and market. Insilico, having secured commitments worth over $5 billion in aggregate across its Lilly and SK partnerships in a single year, has become the clearest proof-of-concept for generative AI in drug discovery at scale.

Deal Structure & Financial Terms

The agreement is structured as a heavily backloaded partnership. Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments, with the vast majority of the $2.5 billion total value contingent on successful development, regulatory, and commercial outcomes .

• Upfront and near-term milestones: Up to $18 million .
• Total potential value: Over $2.5 billion including development, regulatory, and commercial milestone payments .
• Royalties: Insilico will receive single-digit royalties on net sales upon commercialization .
• Revenue-sharing: Additional revenue-sharing income is included in the potential value .
• Scale context: This is Insilico's second deal exceeding $2 billion in under three months .

Therapeutic Focus: CNS Neuroimmune Disorders

The collaboration targets central nervous system (CNS) neuroimmune disorders, a therapeutic area with high unmet medical need. The specific disease categories include:

• Neuroinflammatory conditions
• Neurodegenerative conditions (e.g., disorders involving progressive neuronal loss)
• Rare neurological diseases

The companies plan to identify multiple new biological targets and derive drug candidates against them, marking a focused bet on the intersection of immunology and neuroscience — a space historically difficult for traditional drug discovery due to the blood-brain barrier and complex disease biology .

How the Deal Works Operationally

• Insilico's role: Applies its Pharma.AI generative AI platform — including target discovery, molecule generation, and prediction engines — to identify and optimize novel drug candidates for neuroimmune targets .
• SK Biopharmaceuticals' role: Provides development and commercialization infrastructure, including clinical development expertise, regulatory capabilities, and commercial reach, particularly in Asian and global markets .
• Joint work: The agreement is described as a joint research agreement and a wide-ranging R&D partnership, not merely a licensing deal .

Strategic Context for Each Company

For Insilico Medicine:
This is the second mega-deal for Insilico in 2026. In March 2026, it signed a $2.75 billion collaboration with Eli Lilly ($115 million upfront plus up to $2.63 billion in milestones) covering broader therapeutic areas . The SK deal validates Insilico's platform for CNS neuroimmune applications specifically. The deal diversifies Insilico's partnership base beyond big pharma into Asian biotech leaders, and it follows its IPO on the Hong Kong Stock Exchange (ticker 3696.HK) . Insilico's shares rallied on the news .

For SK Biopharmaceuticals:
SK Biopharmaceuticals is a South Korean biotech known for developing and commercializing CNS drugs globally, including its marketed epilepsy drug Xcopri (cenobamate) . This deal is SK's first AI-driven drug discovery partnership and represents its strategic pivot toward integrating AI into its R&D pipeline . It was the first partnership disclosed by a Korean corporation at BIO 2026 . The deal also aligns with a broader SK Group–Nvidia AI alliance that is expanding beyond semiconductors into pharma and biotech. SK Group chairman Lee Dong-hoon has signaled this push, with Nvidia and SK Biopharm exploring joint AI infrastructure work .

Broader Momentum in AI-Driven Drug Discovery

The Insilico–SK Biopharm deal fits into a clear pattern of accelerating, large-scale AI pharma partnerships in 2026:

• Lilly–Nvidia ($1B): In January 2026, Eli Lilly and Nvidia announced a $1 billion co-investment over five years to build an AI innovation lab for drug discovery .
• Lilly–Insilico ($2.75B): In March 2026, Lilly committed up to $2.75 billion to partner with Insilico on AI-discovered drugs .
• AI as infrastructure: Nvidia's BioNeMo platform is being positioned as foundational AI infrastructure for pharma, with multiple partners building on it .
• Capital flowing: In Q1 2026 alone, AI drug discovery companies raised substantial capital, including a $787 million round for Earendil Labs .
• BIO 2026 theme: The convention's opening news was this deal, underscoring that AI-driven discovery is now a central theme at the industry's largest annual gathering .

The key signal: Big pharma and Asian biotech leaders are no longer experimenting with AI — they are committing billions in backloaded milestone structures that tie payments directly to AI-discovered candidates reaching the clinic and market. Insilico, having secured commitments worth over $5 billion in aggregate across its Lilly and SK partnerships in a single year, has become the clearest proof-of-concept for generative AI in drug discovery at scale.